This international phase III trial ( Investigating Torisel As Second-Line Therapy [ INTORSECT ] ) compared the efficacy of temsirolimus ( mammalian target of rapamycin inhibitor ) and sorafenib ( vascular endothelial growth factor receptor [ VEGFR ] tyrosine kinase inhibitor ) as second-line therapy in patients with metastatic renal cell carcinoma ( mRCC ) after disease progression on sunitinib .